Imfinzi Injection, Solution
Product Images NDC 0310-4611

4 FDA label images from Astrazeneca Pharmaceuticals Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Imfinzi (NDC 0310-4611). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A Kaplan-Meier survival curve graph comparing the probability of overall survival (OS) over time from randomization (in months) between IMFINZI and placebo groups. The graph shows two lines, with IMFINZI displaying a higher survival probability than placebo. Below the graph is a table listing the number of patients at risk at various time points for each group.*
FDA Label Image

0310_4611_50 (Image1)

0310_4611_50 (Image1)
IMFINZI (durvalumab) 500 mg/10 mL injection, solution for intravenous use. Single-dose vial with instructions to store at 2 to 8°C and to discard unused vial portion. Label includes pharmacist advisories for dilution and medication guide dispensing. Manufactured by AstraZeneca Pharmaceuticals LP.*
FDA Label Image

Fig2 (Figure2 01)

Fig2 (Figure2 01)
A Kaplan-Meier survival curve depicting the probability of overall survival (OS) over time in months from randomization for patients treated with IMFINZI (Durvalumab) plus chemotherapy compared to chemotherapy alone. The graph includes censored data points and a table below showing the number of patients at risk at different time intervals for both treatment groups.*
FDA Label Image

0310_4500_12 (Image 01)

0310_4500_12 (Image 01)
IMFINZI (durvalumab) injection label showing the 120 mg/2.4 mL (50 mg/mL) single-dose vial. The label includes storage instructions, caution for pharmacist to dispense medication guide, and a reminder to check vial seal integrity before use. The labeler AstraZeneca Pharmaceuticals LP is identified, with a purple and white design.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.